ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
At Week 24, asciminib significantly improved MMR rate compared with bosutinib (25.5% vs 13.2%, respectively) with numerically lower rates of AEs leading to discontinuation, dose adjustment, or the requirement for additional therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 222 KB
Released: December 14, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Key clinical insights from Drs Suzanne Lentzsch and Saad Usmani on individualizing care for patients with MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: June 17, 2021

Downloadable on the evolving role of PI3K inhibitors for patients with relapsed and refractory follicular lymphoma, from Clinical Care Options (CCO)

John M. Burke, MD Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue